Factor VII ELISA Kit, Mouse

1/2
Price:
Size:
Number:

Factor VII ELISA Kit, Mouse: General Information

Product name
Factor VII ELISA Kit, Mouse
Assay type
Solid Phase Sandwich ELISA (quantitative)
Conjugate
HRP
Sample type
Serum
Sensitivity
5.75 pg/mL
Assay range
31.25-2000 pg/mL
Specificity
Recognizes both recombinant and natural Mouse Factor VII
Precision
  Intra-assay Precision
Sample 1 2 3
N 20 20 20
Mean(pg/mL) 123.52 284.84 598.53
SD 2.87 8.80 10.07
CV(%) 2.3% 3.1% 1.7%
  Inter-assay Precision
Sample 1 2 3
N 20 20 20
Mean(pg/mL) 526.14 1,026.70 1,919.12
SD 39.93 61.03 158.19
CV(%) 7.6% 5.9% 8.2%
Recovery
The recovery of Mouse F7 spiked to different levels throughout the range of the assay in related matrices was evaluated.
Sample
serum (n=3)
Average % Recovery
101.09716499383701
Range
93-109%
Linearity
Serum
  Recovery of detected
1:2 93%
1:4 96%
1:8 117%
1:16 123%
Materials provided
1. 96 well microplate coated with Capture Antibody
2. Detection Antibody conjugated to HRP
3. Standards
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
Product overview
This Factor VII ELISA Kit, Mouse is an enzyme-linked immunosorbent assay for the quantitative measurement of Mouse Factor VII protein in Serum . It contains recombinant Mouse Factor VII, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use.
Shipping
This ELISA Kit is shipped at ambient temperature.
Storage
Unopened Kit: Store at 2 - 8℃
Opened/Reconstituted Reagents: Please refer to CoA

Factor VII ELISA Kit, Mouse: Images

This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.
This assay recognizes both recombinant and natural Mouse mFⅦ. The factors listed below were prepared at 187.5 ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed.

Factor VII ELISA Kit, Mouse: Alternative Names

AI132620 ELISA Kit, Mouse; Cf7 ELISA Kit, Mouse; FVII ELISA Kit, Mouse

Factor VII Background Information

Coagulation factor VII, also known as Serum prothrombin conversion accelerator, Factor VII, F7 and FVII, is a member of the peptidase S1 family. Factor VII is one of the central proteins in the coagulation cascade. It is an enzyme of the serine protease class, and Factor VII (FVII) deficiency is the most frequent among rare congenital bleeding disorders. Factor VII contains two EGF-like domains, one Gla (gamma-carboxy-glutamate) domain and one peptidase S1 domain. The main role of factor VII is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels, normally not exposed to the blood stream. The action of the Factor VII is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent and is produced in the liver. Upon vessel injury, tissue factor is exposed to the blood and circulating Factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself. Recombinant activated factor VII (rFVIIa) is a haemostatic agent, which was originally developed for the treatment of haemophilia patients with inhibitors against factor FVIII or FIX. FVIIa binds specifically to endothelial protein C receptor (EPCR), a known cellular receptor for protein C and activated protein C, on the endothelium. rFVIIa is a novel hemostatic agent, originally developed for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully used recently in an increasing number of nonhemophilic bleeding conditions.
Full Name
coagulation factor VII (serum prothrombin conversion accelerator)
References
  • Franchini M, et al. (2007) Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 18(7): 589-93.
  • Lapecorella M, et al. (2008) Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia. 14(6): 1170-5.
  • Grottke O, et al. (2010) Activated recombinant factor VII (rFVIIa). Best Pract Res Clin Anaesthesiol. 24(1): 95-106.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait